YIFAN PHARMACEUTICAL(SZ:002019) Sou Hu Cai Jing·2025-12-09 10:06Core Viewpoint - Yifan Pharmaceutical (002019) has seen its stock price decline by 1.74% to 12.39 yuan as of December 9, 2025, with a total market capitalization of 15.071 billion yuan. The company announced that some of its products have been included in the National Medical Insurance Catalog for 2025, which is expected to enhance market expansion and sales, although it will not have a significant impact on the company's performance in the short term [1]. Group 1 - As of December 9, 2025, Yifan Pharmaceutical's stock closed at 12.39 yuan, down 1.74% from the previous trading day, with a total market value of 15.071 billion yuan [1]. - The stock opened at 12.69 yuan, reached a high of 12.87 yuan, and a low of 12.38 yuan, with a trading volume of 1.69 billion yuan and a turnover rate of 1.59% [1]. - The National Healthcare Security Administration released the 2025 National Basic Medical Insurance Drug Catalog on December 7, 2025, which includes some of the company's products [1]. Group 2 - The products included in the catalog are the Aibegstine α injection (Yilishu) and the cross-linked sodium hyaluronate injection (Yinikon), which are renewals, and the compound Huangdai tablet (Baixuekang), which has been adjusted to the regular national medical insurance catalog [1]. - The inclusion of these products is expected to facilitate market development and increase sales, but it will not significantly impact the company's performance in the short term [1]. - The catalog will be implemented starting January 1, 2026, with specific medical insurance payment standards to be announced officially [1].